SOFIE and GE Well beingCare Enter Licensing Agreement to Develop FAP PET Radiotracers

• A world licensing settlement has been signed for the event and commercialization of SOFIE’s two investigational Gallium-68 and Fluorine-18 Fibroblast Activation Protein Inhibitors (FAPI) radiopharmaceutical diagnostics – [⁶⁸Ga]FAPI-46 and outside-U.S. rights for [¹⁸F]FAPI-74

• FAP is very expressed in most cancers related fibroblasts (CAF), which helps the expansion and unfold of cancerous cells throughout many tumor varieties¹

• SOFIE will keep scientific improvement and commercialization rights for [¹⁸F]FAPI-74 within the U.S. building on momentum from its FAPI Global Outreach Program

  

CHALFONT ST GILES, England, October 11, 2023–(BUSINESS WIRE)–GE Well beingCare at this time introduced an unique international licensing settlement with SOFIE Biosciences (SOFIE), a Virginia, U.S.-based firm, to develop, manufacture and commercialize SOFIE’s Gallium-68 and Fluorine-18 labelled diagnostics focusing on fibroblast activation protein (FAP). Financial phrases weren’t disclosed. Based on this settlement, GE Well beingCare will tackle international rights for [⁶⁸Ga]FAPI-46 and outside-US rights for [¹⁸F]FAPI-74, initially developed at Heidelberg University in Germany, and each at the moment in Phase II scientific trials within the U.S. ([⁶⁸Ga]FAPI-46 (NCT05262855)² and [¹⁸F]FAPI-74 (NCT05641896)³). SOFIE will proceed its scientific improvement and commercialization program with [¹⁸F]FAPI-74 within the U.S.

This press launch options multimedia. View the complete launch right here: https://www.businesswire.com/news/home/20231009674148/en/

Illustrative instance: most cancers related fibroblasts (CAFs) and the tumor microenvironment. (Photo: Business Wire)

FAP is an enzyme extremely expressed in most cancers related fibroblasts (CAF), a key part of the tumor microenvironment which helps the expansion and unfold of cancerous cells. With CAF current in most tumor varieties together with, for instance, breast, pancreatic, colorectal, lung, liver and gastric, the event of FAP-targeted diagnostics holds nice potential in oncology in addition to different situations together with irritation, fibrosis and arthritis⁴.

Story continues

Building on the momentum created by SOFIE’s sponsored trials within the U.S. and FAPI Global Outreach Program which engages with 130 tutorial establishments in 39 nations to unlock FAPI’s scientific utility, GE Well beingCare goals to develop FAP imaging merchandise by scientific trials and in the direction of regulatory submission, and potential commercialization in numerous areas. SOFIE and GE Well beingCare will collaborate on each the event and commercialization processes by a joint steering committee.

Usankar Thiru, Strategy & Evaluation Director with GE Well beingCare’s Pharmaceutical Diagnostics section mentioned: “Working with SOFIE so as to add these FAPI property to our subsequent technology portfolio of investigational targets is a big milestone and aligns with our imaginative and prescient to increase our innovation pipeline to allow precision look after customized remedy resolution making. As a standalone firm, we’re eager to collaborate with corporations like SOFIE on this approach – bringing our measurement, scale and distinctive perspective as a developer, of each radiopharmaceuticals and the scanners wanted to make the most of them, to drive innovation in healthcare to profit sufferers and clinicians.”

Sherly Mosessian, Ph.D, SOFIE’s Chief Scientific Officer, added: “The FAPI household of compounds have proven to have great potential in diagnostic and companion diagnostic use in numerous oncologic and non-oncologic indications. I’m very excited that we’re collaborating with GE Well beingCare, on a worldwide scale, to assist collectively unlock the complete promise of those merchandise.”

GE Well beingCare’s Pharmaceutical Diagnostics section is a world chief in imaging brokers used to assist round 100 million procedures per 12 months globally, equal to a few affected person procedures each second. Its Molecular Imaging portfolio combines established proprietary merchandise throughout cardiology, neurology and oncology.

About GE Well beingCare Technologies Inc.

GE Well beingCare is a number one international medical expertise, pharmaceutical diagnostics, and digital options innovator, devoted to offering built-in options, providers, and knowledge analytics to make hospitals extra environment friendly, clinicians simpler, therapies extra exact, and sufferers more healthy and happier. Serving sufferers and suppliers for greater than 100 years, GE Well beingCare is advancing customized, linked, and compassionate care, whereas simplifying the affected person’s journey throughout the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses assist enhance affected person care from prognosis, to remedy, to monitoring. We are an $18.3 billion business with 50,000 staff working to create a world the place healthcare has no limits.

Follow us on Facebook, LinkedIn, Twitter, Instagram, and Insights for the latest information, or go to our web site for extra data.

About SOFIE Biosciences (SOFIE)

SOFIE’s imaginative and prescient is to enhance affected person outcomes by growing and delivering molecular diagnostics and therapeutics (theranostics). With its sturdy radiopharmaceutical manufacturing and distribution community, mature contract manufacturing providers and excessive worth theranostic mental property, SOFIE is poised to ship on the promise of radiopharmaceuticals. For extra data go to our web site, or contact us by e mail at [email protected].

_______________________________
¹ Xing, F., Saidou, J. and Watabe, Ok. (2010) Cancer related fibroblasts (cafs) in tumor microenvironment, Frontiers in bioscience (Landmark version). Available at: (Accessed: 28 July 2023).
² Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma (FAPI-46 PDAC) – Full Text View – ClinicalTrials.gov. (n.d.). (Accessed: October 4 2023).
³ Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers – Full Text View – ClinicalTrials.gov. (n.d.). (Accessed: October 4 2023).
⁴ Dendl, Ok., Koerber, S. A., Kratochwil, C., Cardinale, J., Finck, R., Dabir, M., Novruzov, E., Watabe, T., Kramer, V., Choyke, P. L., Haberkorn, U., & Giesel, F. L. (2021). FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis? Cancers, 13(19), 4946. https://doi.org/10.3390/cancers13194946. Available at: (Accessed: October 4 2023).

View supply model on businesswire.com: https://www.businesswire.com/news/home/20231009674148/en/

Contacts

GE Well beingCare Media Contact:
Mathilde Bouscaillou
M 033 647 008 271
[email protected]

SOFIE Biosciences:
Dawn Allen
Marketing Manager
[email protected]